Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $681.1 million.

  • BridgeBio Pharma's Cash & Equivalents rose 141.42% to $643.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.0 million, marking a year-over-year increase of 141.42%. This contributed to the annual value of $681.1 million for FY2024, which is 81.18% up from last year.
  • As of FY2024, BridgeBio Pharma's Cash & Equivalents stood at $681.1 million, which was up 81.18% from $375.9 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Cash & Equivalents peaked at $681.1 million during FY2024, and registered a low of $356.1 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $376.7 million (2022), whereas its average is $477.9 million.
  • Per our database at Business Quant, BridgeBio Pharma's Cash & Equivalents decreased by 4.34% in 2022 and then surged by 81.18% in 2024.
  • BridgeBio Pharma's Cash & Equivalents (Yearly) stood at $356.1 million in 2020, then grew by 10.58% to $393.8 million in 2021, then declined by 4.34% to $376.7 million in 2022, then fell by 0.20% to $375.9 million in 2023, then skyrocketed by 81.18% to $681.1 million in 2024.